CmaxInsight Market Intelligence: Market Research Reports

... the clients within 1-2 Business Days. CmaxInsight’s, “Cannabinoid Receptor Type 2 (CB2) Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Cannabinoid Receptor Type 2 (CB2) Agonist to enhance and expand business potential ...

... Business Days. CmaxInsight’s, “Carbonic Anhydrase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Carbonic Anhydrase Inhibitor. Pipeline Covered: This section mentions all the promising ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Carnitine Palmitoyltransferase I (CPT 1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive ... identifying potential partners with progressing projects for Carnitine Palmitoyltransferase I (CPT 1) Inhibitor to enhance and expand business ...

... Business Days. CmaxInsight’s, “Casein Kinase 2 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Casein Kinase 2 Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Caspase 3 (CPP32, Apopain or YAMA) Activators-Pipeline Intelligence, 2019”, report provides comprehensive ... by identifying potential partners with progressing projects for Caspase 3 (CPP32, Apopain or YAMA) Activators to enhance and expand business ...

... within 1-2 Business Days. CmaxInsight’s, “Caspases Activators-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the Caspases Activators. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “Caspases Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the Caspases Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Days. CmaxInsight’s, “Catechol-O-methyltransferase (COMT) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... to understand the landscape of the Catechol-O-methyltransferase (COMT) Inhibitor. Pipeline Covered: This section mentions all the ...

... 1-2 Business Days. CmaxInsight’s, “Cathepsin K/S Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Cathepsin K/S Inhibitor. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “Cathepsin K Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Cathepsin K Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... 1-2 Business Days. CmaxInsight’s, “Cathepsin S inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Cathepsin S inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “CCR Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CCR Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “CCR1 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CCR1 Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “CCR2 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CCR2 Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “CCR3 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CCR3 Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “CCR4 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CCR4 Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “CCR5 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CCR5 Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “CD (Cluster of Differentiation) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence CD (Cluster of Differentiation) Inhibitor R&D Please note: Certain sections in the ...

... 1-2 Business Days. CmaxInsight’s, “CD 19 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CD 19 Inhibitor. Pipeline Covered: This section mentions all the promising therapies in ...

... 1-2 Business Days. CmaxInsight’s, “CD 3 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the CD 3 Inhibitor. Pipeline Covered: This section mentions all the promising therapies in ...

... 1-2 Business Days. CmaxInsight’s, “CD 33 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CD 33 Inhibitor. Pipeline Covered: This section mentions all the promising therapies in ...

... 1-2 Business Days. CmaxInsight’s, “CD 40 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CD 40 Inhibitor. Pipeline Covered: This section mentions all the promising therapies in ...

... within 1-2 Business Days. CmaxInsight’s, “CD152 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CD152 Inhibitor. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “CD40 Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the CD40 Agonist. Pipeline Covered: This section mentions all the promising therapies ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor-Pipeline Intelligence, 2019”, report provides ... by identifying potential partners with progressing projects for Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor to enhance and ...

... Business Days. CmaxInsight’s, “Cell Wall Synthesis Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Cell Wall Synthesis Inhibitor. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “cFMS Kinase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the cFMS Kinase Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... 1-2 Business Days. CmaxInsight’s, “Checkpoint Kinase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Checkpoint Kinase Inhibitor. Pipeline Covered: This section mentions all the promising ...

... clients within 1-2 Business Days. CmaxInsight’s, “Checkpoint Kinase 1 (Chk1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Checkpoint Kinase 1 (Chk1) Inhibitor R&D Please note: Certain sections in the ...

... clients within 1-2 Business Days. CmaxInsight’s, “Checkpoint Kinase 2 (Chk2) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Checkpoint Kinase 2 (Chk2) Inhibitor R&D Please note: Certain sections in the ...

... Business Days. CmaxInsight’s, “Chemokine Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Chemokine Receptor Antagonist. Pipeline Covered: This section mentions all the promising ...

... coverage of MoA enables the client to understand the landscape of the Cholecystokinin Receptor (CCK) Antagonist. Pipeline Covered: This section mentions all the promising therapies in different ...

... Business Days. CmaxInsight’s, “Cholesterol Absorption Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Cholesterol Absorption Inhibitor. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “Cholesterylester Transfer Protein (CETP) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Cholesterylester Transfer Protein (CETP) Inhibitor R&D Please note: Certain sections in ...

... 1-2 Business Days. CmaxInsight’s, “C-Raf Kinase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the C-Raf Kinase Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... 1-2 Business Days. CmaxInsight’s, “CRF1 Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the CRF1 Receptor Antagonist. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “CXCR4 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the CXCR4 Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Cyclin-Dependent Kinase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Cyclin-Dependent Kinase Inhibitor. Pipeline Covered: This section mentions all the ...

... clients within 1-2 Business Days. CmaxInsight’s, “Cyclin-Dependent Kinase 1 (CDK1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence Cyclin-Dependent Kinase 1 (CDK1) Inhibitor R&D Please note: Certain sections in the ...

... clients within 1-2 Business Days. CmaxInsight’s, “Cyclin-Dependent Kinase 2 (CDK2) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence Cyclin-Dependent Kinase 2 (CDK2) Inhibitor R&D Please note: Certain sections in the ...

... within 1-2 Business Days. CmaxInsight’s, “Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor R&D Please note: Certain sections in the ...

... clients within 1-2 Business Days. CmaxInsight’s, “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence Cyclin-Dependent Kinase 9 (CDK9) Inhibitor R&D Please note: Certain sections in the ...

... within 1-2 Business Days. CmaxInsight’s, “Cyclophilin Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ... client to understand the landscape of the Cyclophilin Inhibitor. Pipeline Covered: This section mentions all the promising ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor-Pipeline Intelligence, 2019”, report ... potential partners with progressing projects for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor to enhance and ...

... clients within 1-2 Business Days. CmaxInsight’s, “Cystic Fibrosis Transmembrane Conductance Regulators (CFTR)-Pipeline Intelligence, 2019”, report provides comprehensive ... identifying potential partners with progressing projects for Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) to enhance and expand ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Cytochrome P450 Superfamily (CYP or CYP450) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive ... by identifying potential partners with progressing projects for Cytochrome P450 Superfamily (CYP or CYP450) Inhibitor to enhance and expand ...

... clients within 1-2 Business Days. CmaxInsight’s, “Cytochrome P450 17 (CYP17) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Cytochrome P450 17 (CYP17) Inhibitor R&D Please note: Certain sections in the ...

... within 1-2 Business Days. CmaxInsight’s, “D Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the D Agonist. Pipeline Covered: This section mentions all the promising therapies in ...

... within 1-2 Business Days. CmaxInsight’s, “D Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the D Antagonist. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “D1 Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the D1 Agonist. Pipeline Covered: This section mentions all the promising therapies in ...